Paraoxonase 2 (PON2) polymorphisms and Parkinson's disease

被引:3
|
作者
Costa, LG [1 ]
Kelada, SN
Costa-Mallen, P
Farin, FM
Viernes, HA
Weller, TS
Franklin, GM
Longstreth, WT
Swanson, PD
Checkoway, H
Furlong, CE
机构
[1] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA
[2] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[4] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA
[5] Univ Washington, Dept Med, Seattle, WA 98195 USA
关键词
paraoxonase; 2; Parkinson's disease; oxidative stress;
D O I
10.1002/nrc.20008
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Oxidative stress may contribute to the pathogenesis of Parkinson's disease (PD). Paraoxonase 2 (PON2) is an ubiquitously expressed protein which displays antioxidant properties, though it does not have paraoxonase or arylesterase activity like other members of the PON gene family, such as PON1. Two coding region polymorphisms (Cys311Ser and Ala14Gly) of the PON2 gene were investigated by a newly developed method in a population-based case-control study of 179 PD patients and 293 controls. No statistically significant differences were found in the distribution of the wild type and mutant alleles between controls and PD. Similarly, no interactions between PON2 and two PON1 polymorphisms (192 and -108) were found. Polymorphisms of PON2 do not appear to be a risk factor for PD.
引用
收藏
页码:130 / 135
页数:6
相关论文
共 50 条
  • [21] The Role of Paraoxonase 2 (PON2) in Mitochondrial Membrane Phospholipid Composition and Lipid Peroxidation
    Sulaiman, Dawoud
    Papesh, Jeremy C.
    Meriwether, David
    Reddy, Srinivasa T.
    CIRCULATION RESEARCH, 2019, 125
  • [22] Expression of the Anti-Oxidative Protein Paraoxonase 2 (PON2) in Malignant Lymphoma
    Udager, A. M.
    Rolland, D.
    Keyoumarsi, F.
    Thomas, D. G.
    Elenitoba-Johnson, K. S. J.
    Lim, M. S.
    Bailey, N. G.
    LABORATORY INVESTIGATION, 2013, 93 : 364A - 364A
  • [23] Expression of the Anti-Oxidative Protein Paraoxonase 2 (PON2) in Malignant Lymphoma
    Udager, A. M.
    Rolland, D.
    Keyoumarsi, F.
    Thomas, D. G.
    Elenitoba-Johnson, K. S. J.
    Lim, M. S.
    Bailey, N. G.
    MODERN PATHOLOGY, 2013, 26 : 364A - 364A
  • [24] Genetic association of PON2 polymorphisms with susceptibility to preterm birth
    Liu, Bo
    Gao, Fengchun
    Wang, Min
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (02): : 2259 - 2264
  • [25] PARAOXONASE-2 GENE (PON2) S311C POLYMORPHISM ASSOCIATED WITH TYPE 2 DIABETIC MELLITUS AND CORONARY HEART DISEASE
    Peerapatdit, T.
    Likidlilid, A.
    Hobang, N.
    Tresukosol, D.
    Ratanamaneechat, S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 34 - 34
  • [26] Interactome of Paraoxonase PON2 Reveals New Pathways for Tumor Growth Regulation
    V. D. Karlov
    N. B. Pestov
    M. I. Shakhparonov
    T. V. Korneenko
    Doklady Biochemistry and Biophysics, 2023, 508 : 31 - 36
  • [27] Interaction of the paraoxonase genes PON1 and PON2 and the methyltetrahydrofolate reductase gene and association with angiographic coronary artery disease
    Reilly, MP
    Wolfe, ML
    Newberg, LP
    Delemos, AS
    Vishnupad, P
    Mohler, ER
    Pohl, M
    Grant, D
    Matthai, W
    Wilensky, RL
    Boyce-Jacino, M
    Rader, DJ
    CIRCULATION, 2000, 102 (18) : 278 - 278
  • [28] Paraoxonase 2 (PON2) deficiency leads to RPE mitochondrial dysfunction and retinal degeneration.
    Sreekumar, Parameswaran G.
    Su, Feng
    Hong, Elise
    Handa, James T.
    Ferrington, Deborah A.
    Reddy, Srinivasa T.
    Kannan, Ram
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [29] Interactome of Paraoxonase PON2 Reveals New Pathways for Tumor Growth Regulation
    Karlov, V. D.
    Pestov, N. B.
    Shakhparonov, M. I.
    Korneenko, T. V.
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2023, 508 (01) : 31 - 36
  • [30] Macrophage endoplasmic reticulum (ER) proteins and reducing elements stabilize paraoxonase 2 (PON2)
    Rosenblat, Mira
    Volkova, Nina
    Aviram, Michael
    ATHEROSCLEROSIS, 2010, 213 (02) : 408 - 414